{"id":4350,"date":"2025-08-19T14:31:34","date_gmt":"2025-08-19T11:31:34","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=4350"},"modified":"2025-08-19T15:44:33","modified_gmt":"2025-08-19T12:44:33","slug":"itf-therapeutics-launching-a-study-to-evaluate-the-real-world-experience-of-duvyzat-givinostat-in-patients-with-duchenne-muscular-dystrophy","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/itf-therapeutics-launching-a-study-to-evaluate-the-real-world-experience-of-duvyzat-givinostat-in-patients-with-duchenne-muscular-dystrophy\/","title":{"rendered":"ITF Therapeutics, Duchenne Musk\u00fcler Distrofisi Olan Hastalarda Duvyzat'\u0131n (Givinostat) Ger\u00e7ek D\u00fcnya Deneyimini De\u011ferlendirmek \u0130\u00e7in Bir \u00c7al\u0131\u015fma Ba\u015flat\u0131yor"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Bu prospektif g\u00f6zlemsel \u00e7al\u0131\u015fman\u0131n (NCT07127978) amac\u0131, Amerika Birle\u015fik Devletleri&#039;nde standart klinik bak\u0131m\u0131n bir par\u00e7as\u0131 olarak ilk kez oral Duvyzat (Givinostat) tedavisine ba\u015flayan veya alt\u0131 ay i\u00e7inde tedaviye ba\u015flam\u0131\u015f olan DMD hastalar\u0131n\u0131n g\u00fcvenli\u011fini, tolere edilebilirli\u011fini ve fonksiyonel sonu\u00e7lar\u0131n\u0131 de\u011ferlendirmektir. 24 ayl\u0131k kay\u0131t s\u00fcresi ve en az iki y\u0131ll\u0131k takip s\u00fcresiyle, \u00e7al\u0131\u015fman\u0131n ilk kat\u0131lan hastalar i\u00e7in be\u015f y\u0131la kadar s\u00fcrmesi beklenmektedir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Daha fazla bilgi edin<\/strong>: <a href=\"https:\/\/dmdwarrior.com\/tr\/duvyzat-givinostat-nonsteroidal-drug\/\" target=\"_blank\" rel=\"noreferrer noopener\">Duvyzat (Givinostat) Nedir?<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00c7al\u0131\u015fmaya 300 kat\u0131l\u0131mc\u0131 (180&#039;i y\u00fcr\u00fcyemeyen ve 120&#039;ye kadar y\u00fcr\u00fcyebilen hasta) dahil edilecektir. Kat\u0131l\u0131mc\u0131lar en az iki y\u0131l boyunca takip edilecek ve veriler rutin klinik ziyaretler s\u0131ras\u0131nda toplanacakt\u0131r. De\u011ferlendirmeler aras\u0131nda laboratuvar parametreleri (\u00f6rne\u011fin, trombosit say\u0131s\u0131, trigliseritler), kardiyak ve pulmoner fonksiyon, hasta taraf\u0131ndan bildirilen sonu\u00e7lar ve North Star Ambulatuvar De\u011ferlendirme (NSAA) ve \u00dcst Ekstremite Performans\u0131 (PUL) \u00f6l\u00e7e\u011fi gibi motor fonksiyon \u00f6l\u00e7ekleri yer almaktad\u0131r.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Duvyzat (Givinostat) \u00c7al\u0131\u015fmas\u0131 \u2013 NCT07127978 \u2013<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Bu \u00e7al\u0131\u015fma Duchenne Musk\u00fcler Distrofisi olan hastalarda Givinostat&#039;\u0131n Ger\u00e7ek D\u00fcnya Deneyimini de\u011ferlendirmektedir. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c7al\u0131\u015fma Ba\u015flang\u0131c\u0131 (Tahmini)<\/strong>: 2025-09-15<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Birincil Tamamlanma (Tahmini):<\/strong> 2030-06-30<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c7al\u0131\u015fman\u0131n Tamamlanmas\u0131 (Tahmini)<\/strong>: 2030-07-30<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Kat\u0131l\u0131mc\u0131 Say\u0131s\u0131 (Tahmini)<\/strong>: 300<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c7al\u0131\u015fma T\u00fcr\u00fc<\/strong>: G\u00f6zlemsel<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Konumlar<\/strong>: Hen\u00fcz konum verisi yok.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00c7al\u0131\u015fmaya Uygun Ya\u015flar<\/strong>: 6 Ya\u015f ve \u00fczeri (\u00c7ocuk, Yeti\u015fkin, Ya\u015fl\u0131 Yeti\u015fkin)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Temel dahil etme ve hari\u00e7 tutma kriterleri. \u2013 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07127978\" target=\"_blank\" rel=\"noreferrer noopener\">NCT07127978<\/a> \u2013<\/p>","protected":false},"excerpt":{"rendered":"<p>The purpose of this prospective observational study (NCT07127978) is to assess the safety, tolerability, and functional results of DMD patients who are starting oral Duvyzat (Givinostat) for the first time or who have already begun therapy within six months as part of standard clinical care in the United States. With a 24-month enrollment period and [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4353,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[46,47],"class_list":["post-4350","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-duvyzat","tag-givinostat"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/4350","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=4350"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/4350\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/4353"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=4350"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=4350"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=4350"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}